T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)
A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer
Sponsor: University of Zurich
Listed as NCT03458117, this PHASE1 trial focuses on Basal Cell Carcinoma and Cutaneous Lymphoma and remains completed. Sponsored by University of Zurich, it has been updated 8 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE1
Status: Unknown Status → Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Zurich
For direct contact, visit the study record on ClinicalTrials.gov .